Risk of leaks of clinical-trial information and system failures
First written in FY2016. 3 of 8 entries say "Mitigated", first in 2026-05-08. Latest entry: 2026-09-17.
0 other companies' latest entry also says "Materialised".
- 2026-09-17MaterialisedOther Disclosures
「At approximately 14:35 on Wednesday, 16 September 2026, a failure occurred at the server outsourced to manage the Company's website (https://www.oncotherapy.co.jp/), and the website remains inaccessible.」
The information management and system failure risk previously disclosed materialized as an actual server failure affecting the Company's website. The canonical thread remains unchanged. - FY2026MitigatedAnnual report
「In addition, CPM Co. obtained CAP (College of American Pathologists) accreditation, the global standard for quality control in clinical testing, for its clinical testing business at CPM Clinical Lab, and certification under ISO/IEC 27001:2022, the international standard for information security management systems (ISMS), for its contract testing business.」
To address information-management risks in its clinical testing and contract analysis businesses, CPM Co. obtained ISO/IEC 27001:2022 certification, the international ISMS standard. - FY2025RestatedAnnual report
「The company's group manages by computer confidential information, including information on clinical trials in which the company is involved, information on large-scale cancer genetic analysis testing, other personal information and personal genetic information.」
The company continues to disclose the risks of information leaks and system failures involving clinical trial information, large-scale genetic analysis information, personal information and personal genetic information. - FY2018WorsenedAnnual report
「The company's group manages by computer confidential information, including information on clinical trials in which the company is involved, information on large-scale cancer genetic analysis testing, other personal information and personal genetic information.」
The scope of information-management risk expanded beyond clinical trial information to include large-scale genetic analysis information and personal genetic information. - FY2017RestatedAnnual report
「The company establishes rules and other procedures, ensures that employees are thoroughly informed of the importance of information management, sets a high level of system security and conducts continuous monitoring. However, if systems used by the company as a whole become unable to operate normally due to the destruction or failure of communications infrastructure, or if an information leak or defect occurs, the social credibility, operating results and financial condition of the company's group may be affected.」
The company continues to disclose information-management risks and its responses through rules, training, security settings and continuous monitoring. - FY2016First statedAnnual report
「Information leaks or defects could affect the social credibility, operating results and financial condition of the company's group.」
The company identifies the establishment of rules, employee training, security settings and continuous monitoring as countermeasures.